Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study

医学 鲁索利替尼 骨髓纤维化 内科学 析因分析 耐受性 队列 国际预后积分系统 临床终点 临床研究阶段 临床试验 贫血 肿瘤科 骨髓 骨髓增生异常综合症 不利影响
作者
Naveen Pemmaraju,Jacqueline S. Garcia,Jalaja Potluri,Jason G. Harb,Yan Sun,Paul Jung,Qin Q. Qin,Srinivas K. Tantravahi,Srđan Verstovšek,Claire Harrison
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:9 (6): e434-e444 被引量:37
标识
DOI:10.1016/s2352-3026(22)00116-8
摘要

Primary analyses of cohort 1a of the REFINE trial showed that addition of navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume (SVR35) and reduced symptoms in patients with myelofibrosis no longer benefiting from ruxolitinib. Here, we report the exploratory post-hoc biomarker analyses from cohort 1a.REFINE is a phase 2, multicentre, open-label trial designed to assess the activity and safety of navitoclax alone or in combination with ruxolitinib in patients with primary or secondary (post-polycythaemia vera or post-essential thrombocythaemia) myelofibrosis. Cohort 1a of the study included patients who had disease progression or suboptimal response on stable ruxolitinib monotherapy. Patients in cohort 1a, who had previously received ruxolitinib for 12 weeks or more, continued their current stable dose, and navitoclax was orally administered at 50 mg per day and escalated weekly to a maximum of 300 mg per day, based on tolerability. The primary activity endpoint was SVR35 at week 24 from baseline. Secondary endpoints were a 50% or greater reduction in total symptom score (TSS50) at week 24 from baseline as measured by the Myelofibrosis Symptom Assessment Form (version 4.0), anaemia response assessed according to International Working Group-Myeloproliferative Neoplasms Research and European LeukemiaNet criteria, and change in grade of bone marrow fibrosis according to the European consensus grading system; and exploratory endpoints included overall survival and changes in inflammatory cytokines. Exploratory analyses investigated potential prognostic biomarkers of the benefit of navitoclax-based combination treatment, including bone marrow fibrosis and variant allele frequency, in patients with a suboptimal response to ruxolitinib. This study is registered with ClinicalTrials.gov (NCT03222609) and is ongoing.Between Nov 14, 2017, and April 10, 2019, 34 patients in cohort 1a received at least one dose of navitoclax plus ruxolitinib. 23 (68%) patients were male, with 32 (94%) being White. At data cutoff (May 6, 2021), the median follow-up for survivors was 26·2 months (IQR 21·9-32·3). 33 patients were evaluable for biomarker analyses; 19 (58%) had high molecular risk mutations. Five (31%) of 16 patients had SVR35 at week 24 in the high molecular risk group, as did four (31%) of 13 in the non-high molecular risk group. Four (36%) of 11 patients in the high molecular risk group had TSS50 at week 24 compared with two (25%) of eight in the non-high molecular risk group; seven (39%) of 18 in the high molecular risk group had an improvement in fibrosis by at least one grade compared with five (36%) of 14 in the non-high molecular risk group; and four (28%) of 14 had reductions in variant allele frequency of 20% or greater in the high molecular risk group compared with two (17%) of 12 in the non-high molecular risk group. Patients with improvements in fibrosis of one grade or more and a reduction of 20% of more in variant allele frequency had improved overall survival (median overall survival not reached) compared with those who did not achieve fibrosis improvement or a reduction in variant allele frequency (median overall survival 28·5 months [95% CI 19·6-not estimable] for both), suggesting potential disease modification. Additionally, changes in concentrations of β-2-microglobulin (week 12: r=0·57; week 24: r=0·57), TIMP metallopeptidase inhibitor 1 (week 12: r=0·47; week 24: r=0·54), TNF receptor type II (r=0·55; week 24: r=0·40), and vascular cell adhesion molecule-1 (r=0·58; week 24: r=0·50) were positively associated with changes in spleen volume.These biomarker analyses reveal clinically meaningful splenic responses independent of high molecular risk mutation status in patients treated with navitoclax plus ruxolitinib who were not benefiting from ruxolitinib monotherapy. Furthermore, the overall survival benefit observed in those with an improvement in fibrosis or a reduction in variant allele frequency is suggestive of disease modification, implying the therapeutic potential of adding navitoclax to ruxolitinib for patients with myelofibrosis who had disease progression or suboptimal response to ruxolitinib monotherapy.AbbVie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嗒嗒完成签到,获得积分10
刚刚
研友_huang发布了新的文献求助10
刚刚
星辰大海应助风趣黑裤采纳,获得10
刚刚
刚刚
俭朴紫寒发布了新的文献求助10
1秒前
2秒前
付创发布了新的文献求助10
3秒前
大个应助爱蹭热度小美采纳,获得10
5秒前
勤恳慕蕊完成签到,获得积分10
6秒前
Coral.发布了新的文献求助10
6秒前
bean完成签到,获得积分10
7秒前
阿桓完成签到 ,获得积分10
8秒前
8秒前
寒冷寻桃完成签到 ,获得积分10
9秒前
9秒前
自由的馒头完成签到,获得积分10
9秒前
wei发布了新的文献求助10
11秒前
12秒前
量子星尘发布了新的文献求助10
13秒前
烂漫煎饼完成签到,获得积分10
13秒前
zing发布了新的文献求助30
14秒前
HFan完成签到,获得积分10
15秒前
华仔应助秀丽的千山采纳,获得50
15秒前
dou发布了新的文献求助10
17秒前
小鱼儿完成签到,获得积分20
18秒前
AZE应助玛卡巴卡采纳,获得10
19秒前
num5thWindMaster完成签到,获得积分10
20秒前
21秒前
希望天下0贩的0应助wei采纳,获得10
21秒前
Miss67完成签到,获得积分10
21秒前
张志迪发布了新的文献求助10
21秒前
顺利夏之完成签到 ,获得积分10
21秒前
斯文败类应助唐水之采纳,获得10
21秒前
zing完成签到,获得积分20
24秒前
24秒前
我是老大应助球球w采纳,获得10
24秒前
25秒前
李可爱发布了新的文献求助10
25秒前
25秒前
烟花应助dou采纳,获得10
27秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 1000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3978061
求助须知:如何正确求助?哪些是违规求助? 3522192
关于积分的说明 11211969
捐赠科研通 3259468
什么是DOI,文献DOI怎么找? 1799621
邀请新用户注册赠送积分活动 878477
科研通“疑难数据库(出版商)”最低求助积分说明 806918